Cargando…

Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors

BACKGROUND: For stereotactic body radiotherapy (SBRT) to central (C) and ultracentral (UC) lung tumors, our provincial practice has been to prioritize organs at risk (OARs) constraints by compromising target volume coverage if needed. The objectives are to report the treatment’s efficacy and safety....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yizhou, Khawandanh, Eman, Thomas, Steven, Zhang, Susan, Dunne, Emma M., Liu, Mitchell, Schellenberg, Devin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047404/ https://www.ncbi.nlm.nih.gov/pubmed/32106868 http://dx.doi.org/10.1186/s13014-020-01491-w

Ejemplares similares

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer
por: Yang, Dan, et al.
Publicado: (2020)

Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors
por: Owen, Dawn, et al.
Publicado: (2020)

An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
por: Zarębska, Izabela, et al.
Publicado: (2023)

Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
por: Regnery, Sebastian, et al.
Publicado: (2020)

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity
por: Rock, Crosby, et al.
Publicado: (2023)

Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis
por: Rim, Chai Hong, et al.
Publicado: (2020)

Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study
por: Aoki, Shuri, et al.
Publicado: (2018)

Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)
por: Regnery, Sebastian, et al.
Publicado: (2022)

External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
por: Chen, Ishita, et al.
Publicado: (2022)

Hypofractionated High-Dose Intensity-Modulated Radiotherapy (60 Gy at 2.5 Gy per Fraction) for Recurrent Renal Cell Carcinoma: A Case Report
por: Cho, Jaeho, et al.
Publicado: (2008)

Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
por: Han, Dan, et al.
Publicado: (2015)

30 GY IN 4 STEREOTACTIC BODY RADIOTHERAPY (SBRT) FRACTIONS FOR COMPLEX SPINAL METASTASES: MATURE OUTCOMES SUPPORTING THIS NOVEL REGIMEN
por: Moore-Palhares, Daniel, et al.
Publicado: (2023)

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions
por: Sandoval, Maria L., et al.
Publicado: (2023)

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases
por: Yeung, Rosanna, et al.
Publicado: (2017)

Biologically effective doses of 60–70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial
por: Ye, Yusheng, et al.
Publicado: (2022)

Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer
por: Akiyama, Hironori, et al.
Publicado: (2012)

Randomized Pilot Study of 20 Gy in 5 Fractions versus 27 Gy in 3 Fractions Radiotherapy for Treating Painful Bone Metastases: A Single Institution Experience
por: Sakr, Amr, et al.
Publicado: (2020)

Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial
por: Henke, Lauren E., et al.
Publicado: (2018)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer
por: Karasawa, Kumiko, et al.
Publicado: (2013)

Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions
por: Ermiş, Ekin, et al.
Publicado: (2015)

Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83–100 Gy in five fractions
por: Takeda, Atsuya, et al.
Publicado: (2016)

Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction
por: Lee, Tae Hoon, et al.
Publicado: (2022)

Doses, fractionations, constraints for stereotactic radiotherapy
por: Borghesi, Simona, et al.
Publicado: (2022)

A retrospective study of sinonasal tumors in 182 dogs treated with stereotactic radiotherapy (3 × 10 Gy) (2010‐2015)
por: Yoshikawa, Hiroto, et al.
Publicado: (2023)

Simulating the Potential of Model-Based Individualized Prescriptions for Ultracentral Lung Tumors
por: Chen, Ishita, et al.
Publicado: (2023)

Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
por: Murrell, Donna H., et al.
Publicado: (2018)

Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume
por: Takeda, Atsuya, et al.
Publicado: (2014)

Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity
por: Murthy, Vedang, et al.
Publicado: (2017)

EXTERNAL BEAM RADIOTHERAPY FOR PAINFUL BONE METASTASES FROM HEPATOCELLULAR CARCINOMA: MULTIPLE FRACTIONS COMPARED WITH AN 8-GY SINGLE FRACTION
por: HAYASHI, SHINYA, et al.
Publicado: (2014)

Exceeding Radiation Dose to Volume Parameters for the Proximal Airways with Stereotactic Body Radiation Therapy Is More Likely for Ultracentral Lung Tumors and Associated with Worse Outcome
por: Farrugia, Mark, et al.
Publicado: (2021)

12 × 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma?
por: Lubgan, Dorota, et al.
Publicado: (2021)

Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas
por: Elhateer, H., et al.
Publicado: (2008)

Fractionated stereotactic radiotherapy for pediatric patients with retinoblastoma
por: Higgins, Patrick D., et al.
Publicado: (2006)

Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy
por: Vasudevan, Harish N., et al.
Publicado: (2017)

The Quest for Optimal Fractionation Schedules in Stereotactic Radiotherapy
por: Shibamoto, Yuta, et al.
Publicado: (2020)

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
por: Kim, Yeon Joo, et al.
Publicado: (2018)

Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54–56 Gy given in 9–7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size
por: Aoki, Masahiko, et al.
Publicado: (2015)

Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy
por: Oie, Yumi, et al.
Publicado: (2021)

Prospective In Silico Evaluation of Cone-Beam Computed Tomography-Guided StereoTactic Adaptive Radiation Therapy (CT-STAR) for the Ablative Treatment of Ultracentral Thoracic Disease
por: Schiff, Joshua P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0uhcnpng4jvjmv33o8s3b374pc